Evidence map›Paper›PMID 33994107›Full record

ArticleTransfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis2021

Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.

Giustina De Silvestro, Giorgio Gandini, Francesco Fiorin, Piero Marson, Ersilia Barbone, Andrea Frigato, Gianluca Gessoni, Arianna Veronesi, Monia Pacenti, Monica Castelli and 4 more

Abstract read
In one paragraph

Article in Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Giustina De SilvestroTransfusion Medicine Department of Padova, University Hospital of Padova, Italy. Electronic address: giustina.desilvestro@aopd.veneto.it.
Giorgio GandiniTransfusion Medicine Department of Verona, University Hospital of Verona, Italy.
Francesco FiorinTransfusion Medicine Department of Vicenza, San Bortolo Hospital of Vicenza, Italy.
Piero MarsonTransfusion Medicine Department of Padova, University Hospital of Padova, Italy.
Ersilia BarboneTransfusion Medicine Department of Belluno, San Martino Hospital of Belluno, Italy.
Andrea FrigatoTransfusion Medicine Department of Rovigo, S. Maria della Misericordia Hospital of Rovigo, Italy.
Gianluca GessoniTransfusion Medicine Department of Venezia, Dell'Angelo Hospital of Mestre (Venice), Italy.
Arianna VeronesiTransfusion Medicine Department of Treviso, Ca' Foncello Hospital of Treviso, Italy.
Monia PacentiInstitute of Microbiology and Virology, University Hospital of Padova, Italy.
Monica CastelliTransfusion Medicine Department of Vicenza, San Bortolo Hospital of Vicenza, Italy.
Marianna RinaldiTransfusion Medicine Department of Verona, University Hospital of Verona, Italy.
Monica RizziTransfusion Medicine Department of Verona, University Hospital of Verona, Italy.
Francesca StefaniTransfusion Medicine Department of Vicenza, San Bortolo Hospital of Vicenza, Italy.
Giovanni RoveroniGeneral Healthcare of the Veneto Region (Azienda Zero), Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConvalescent plasma (CP) has been used in the past in various pandemics, in particular in H1N1, SARS and MERS infections. In Spring 2020, when ongoing the SARS-CoV-2 pandemics, the Veneto Region (V-R) has proposed setting-up an anti-SARS-CoV-2 CP (CCP) Bank, with the aim of preparing a supply of CCP immediately available in case of subsequest epidemic waves. MATERIALS AND

methodsKey-points to be developed for a quick set-up of the V-R CCP Bank have been recruitment of donors recovered from COVID-19 infection, laboratory analysis for the biological qualification of the CCP units, including titre of neutralizing antibodies and reduction of pathogens, according to National Blood Centre (CNS) Directives, adaptation of the V-R Information Technology systems and cost analysis. Some activities, including diagnostic and viral inactivation processes, have been centralized in 2 or 3 sites. Laboratory analysis upon preliminary admission of the donor included all tests required by the Italian laws and the CNS directives.

resultsFrom April to August 2020, 3,298 people have contacted the V-R Blood Transfusion Services: of these, 1,632 have been evaluated and examined as first time donors and those found to be suitable have carried out 955 donations, from which 2,626 therapeutic fractions have been obtained, at a cost around 215,00 Euro. Since October 2020, the number of COVID-19 inpatients has had a surge with a heavy hospital overload. Moreover, the high request of CCP therapy by clinicians has been just as unexpected, showing a wide therapeutic use.

conclusionsThe organizational model here presented, which has allowed the rapid collection of a large amount of CCP, could be useful when facing new pandemic outbreaks, especially in low and middle income countries, with generally acceptable costs.

Indexed as

PandemicsAntibodies, NeutralizingAntibodies, ViralBlood BanksBlood-Borne InfectionsBlood DonorsBlood SafetyCivil DefenseCosts and Cost AnalysisCOVID-19COVID-19 SerotherapyDonor SelectionHumansImmunization, PassiveItalyModels, OrganizationalAntibodies, NeutralizingAntibodies, ViralBlood bankingConvalescent plasmaCost analysisCOVID-19Organizational model

Identifiers

PMID33994107
PMCPMC8103741

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.